Download full-text PDF |
Source |
---|
ACS Appl Mater Interfaces
January 2025
Department of Chemistry, BITS Pilani, Pilani Campus, Pilani, Rajasthan 333031, India.
Accurate oxygen detection and measurement of its concentration is vital in biological and industrial applications, necessitating highly sensitive and reliable sensors. Optical sensors, valued for their real-time monitoring, nondestructive analysis, and exceptional sensitivity, are particularly suited for precise oxygen measurements. Here, we report a dual-emissive iridium(III) complex, IrNPh, featuring "aggregation-induced emission" (AIE) properties and used for sensitive oxygen sensing.
View Article and Find Full Text PDFHigh Alt Med Biol
January 2025
The Research Center for High Altitude Medicine, Qinghai University, Xining, China.
Ri-Li Ge. Medical problems of chronic hypoxia in highlanders living on the tibetan plateau. 00:00-00, 2024.
View Article and Find Full Text PDFEur J Neurol
January 2025
Epilepsy Center, Department of Neurology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
Background: Epileptiform activity, including status epilepticus (SE), occurs in up to one-third of comatose survivors of cardiac arrest and may predict poor outcome. The relationship between SE and hypoxic-ischemic brain injury (HIBI) is not established.
Methods: This is a single-center retrospective study on consecutive patients with post-anoxic super-refractory SE.
Exp Physiol
January 2025
Department for Automatics, Biocybernetics and Robotics, Jožef Stefan Institute, Ljubljana, Slovenia.
The physiological sequelae of pre-term birth might influence the responses of this population to hypoxia. Moreover, identifying variables associated with development of acute mountain sickness (AMS) remains a key practically significant area of altitude research. We investigated the effects of pre-term birth on nocturnal oxygen saturation ( ) dynamics and assessed the predictive potential of nocturnal -related metrics for morning AMS in 12 healthy adults with gestational age < 32 weeks (pre-term) and 12 term-born control participants.
View Article and Find Full Text PDFNephrol Dial Transplant
November 2024
Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).
Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!